Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Mr. Thomas Lingelbach is the President of Valneva SE, joining the firm since 2012.
What is the price performance of Valneva SE stock?
The current price of Valneva SE is $6, it has increased 1.18% in the last trading day.
What are the primary business themes or industries for Valneva SE?
Valneva SE belongs to Biotechnology industry and the sector is Health Care
What is Valneva SE market cap?
Valneva SE's current market cap is $521.2M
Is Valneva SE a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Valneva SE, including 4 strong buy, 6 buy, 2 hold, 0 sell, and 4 strong sell